scholarly journals Continuous in Situ Electrochemical Monitoring of Doxorubicin Efflux from Sensitive and Drug-Resistant Cancer Cells

1998 ◽  
Vol 75 (5) ◽  
pp. 2255-2261 ◽  
Author(s):  
Chen Yi ◽  
Miklós Gratzl
Keyword(s):  
Cancer Cells ◽  
Drug Resistant ◽  
Electrochemical Monitoring

scholarly journals Instructed‐assembly of small peptides inhibits drug‐resistant prostate cancer cells

2019 ◽  
Vol 112 (1) ◽  
Author(s):  
Zhaoqianqi Feng ◽  
Huaimin Wang ◽  
Meihui Yi ◽  
Chieh‐Yun Lo ◽  
Ashanti Sallee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Drug Resistant ◽  
Prostate Cancer Cells ◽  
Small Peptides

Silencing PEX26 as an Unconventional Mode to Kill Drug-Resistant Cancer Cells and Forestall Drug Resistance

Autophagy ◽  
2021 ◽  
Author(s):  
Michael S. Dahabieh ◽  
Fan Huang ◽  
Christophe Goncalves ◽  
Raúl Ernesto Flores González ◽  
Sathyen Prabhu ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Cancer Cells ◽  
Drug Resistant

Synthesis and short DNA in situ loading and delivery of 4 nm-aperture flexible organic frameworks

2021 ◽  
Author(s):  
Ze-Kun Wang ◽  
Jia-Le Lin ◽  
Yun-Chang Zhang ◽  
Chen-Wu Yang ◽  
Ya-Kun Zhao ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Water Soluble

Water-soluble hydrazone-connected 3D flexible organic frameworks have been revealed to in situ load and deliver short DNA into normal and cancer cells.

LDH-doped electrospun short fibers enable dual drug loading and multistage release for chemotherapy of drug-resistant cancer cells

2021 ◽  
Author(s):  
Yupei Ma ◽  
Du Li ◽  
Yunchao Xiao ◽  
Zhijun OuYang ◽  
Mingwu Shen ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Cancer Cells ◽  
Cancer Chemotherapy ◽  
Side Effect ◽  
Drug Loading ◽  
Adverse Side Effect ◽  
Drug Resistant ◽  
Short Fibers ◽  
Dual Drug

Conventional cancer chemotherapy is facing difficulties in improving the bioavailability, overcoming the severe adverse side effect of chemotherapeutics and reversing the multidrug resistance of cancer cells. To address these challenges,...

Vagus nerve stimulation for drug-resistant epilepsy

2019 ◽  
Vol 20 (3) ◽  
pp. 189-198 ◽  
Author(s):  
Laura Pérez-Carbonell ◽  
Howard Faulkner ◽  
Sean Higgins ◽  
Michalis Koutroumanidis ◽  
Guy Leschziner
Keyword(s):  
Vagus Nerve ◽  
Seizure Frequency ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Therapeutic Option ◽  
Drug Resistant ◽  
Drug Resistant Epilepsy ◽  
Randomised Controlled

Vagus nerve stimulation (VNS) is a neuromodulatory therapeutic option for drug-resistant epilepsy. In randomised controlled trials, VNS implantation has resulted in over 50% reduction in seizure frequency in 26%–40% of patients within 1 year. Long-term uncontrolled studies suggest better responses to VNS over time; however, the assessment of other potential predictive factors has led to contradictory results. Although initially designed for managing focal seizures, its use has been extended to other forms of drug-resistant epilepsy. In this review, we discuss the evidence supporting the use of VNS, its impact on seizure frequency and quality of life, and common adverse effects of this therapy. We also include practical guidance for the approach to and the management of patients with VNS in situ.

Sign in / Sign up

Export Citation Format

Share Document